Nicotinamide and neurocognitive function

Nutritional Neuroscience

Volumn 18, Issue 5, 2015, Pages 193-200

  Rennie, George ^a   Chen, Andrew C ^a   Dhillon, Haryana ^b   Vardy, Janette ^b,c   Damian, Diona L ^a,d  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ANZAC Research Institute   (Australia)

^d MELANOMA INSTITUTE AUSTRALIA   (Australia)

Author keywords

Memory; Niacinamide; Vitamin B3

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NICOTINIC ACID; QUINOLINIC ACID; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE;

ALZHEIMER DISEASE; BRAIN ISCHEMIA; CELL ENERGY; COGNITIVE DEFECT; DIET SUPPLEMENTATION; HUMAN; MORRIS WATER MAZE TEST; MULTIINFARCT DEMENTIA; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRAUMATIC BRAIN INJURY; UPREGULATION; VITAMIN INTAKE; ANIMAL; COGNITION; DIETARY SUPPLEMENT; DISEASE MODEL; DRUG EFFECTS; NEUROCOGNITIVE DISORDERS;

ANIMALIA;

ANIMALS; COGNITION; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; HUMANS; NEUROCOGNITIVE DISORDERS; NIACINAMIDE;

EID: 84930589328     PISSN: 1028415X     EISSN: 14768305     Source Type: Journal    
DOI: 10.1179/1476830514Y.0000000112     Document Type: Review

References (78)

1. 1 Sauve AA. NAD+ and vitamin B3: from metabolism to therapies. J Pharmacol Exp Ther 2008;324:883–93.
2. 2 Karthikeyan K, Thappa DM. Pellagra and skin. Int J Dermatol 2002;41:476–81.
3. 3 Knip M, Douek IF, Moore WP, Gillmmor HA, McLean AE, Bingley PJ, et al. Safety of high-dose nicotinamide: a review. Diabetologia 2000;43:1337–45.
4. 4 Mutasim DF. Autoimmune bullous dermatoses in the elderly. Drugs Aging 2003;20:663–81.
5. 5 Surjana D, Damian DL. Nicotinamide in dermatology and photoprotection. Skinmed 2011;9:360–5.
6. 6 Surjana D, Halliday GM, Damian DL. Nicotinamide enhances repair of ultraviolet radiation-induced DNA damage in human keratinocytes and ex vivo skin. Carcinogen 2013;34:1144–9.
7. 7 Park J, Halliday GM, Surjana D, Damian DL. Nicotinamide prevents ultraviolet radiation-induced cellular energy loss. Photochem Photobiol 2010;86:942–8.
8. 8 Kripke ML, Cox PA, Alas LG, Yarosh DB. Pyrimidine dimers in DNA initiate systemic immunosuppression in UV-irradiated mice. Proc Natl Acad Sci USA 1992;89:7516–20.
9. 9 Sivapirabu G, Yiasemides E, Halliday GM, Park J, Damian DL. Topical nicotinamide modulates cellular energy metabolism and provides broad-spectrum protection against ultraviolet radiationinduced immunosuppression in humans. Br J Dermatol 2009; 161:1357–64.
10. 10 Surjana D, Halliday GM, Martin AJ, Moloney FJ, Damian DL. Oral nicotinamide reduces actinic keratoses in phase II doubleblinded randomized controlled trials. J Invest Dermatol 2012; 132:1497–500.
11. 11 Scientific Committee on Food. Opinion of the Scientific Committee on food on the tolerable upper intake levels of nicotinic acid and nicotinamide (niacin). European Commission; Brussels, 2002.
12. 12 Safe UpperLevels for Vitamins and Minerals. Expert Group on vitamins and minerals. Food Standards Agency; London, 2003.
13. 13 Hankes L. Nicotinic acid and nicotinamide. In: Machlin L (ed.) Handbook of vitamins. New York: Marcel Dekker; 1984. pp. 329–77.
14. 14 Xu P, Sauve AA. Vitamin B3, the nicotinamide adenine dinucleotides and aging. Mech Ageing Dev 2010;131:287–98.
15. 15 Jacobson EL, Dame AJ, Pyrek JS, Jacobson MK. Evaluating the role of niacin in human carcinogenesis. Biochimie 1995;77:394–8.
16. 16 Guarente L. Sirtuins as potential targets for metabolic syndrome. Nature 2006;444:868–74.
17. 17 Pellat-Deceunynck C, Wietzerbin J, Drapier JC. Nicotinamide inhibits nitric oxide synthase mRNA induction in activated macrophages. Biochem J 1994;297:53–8.
18. 18 Sodhi RK, Singh N, Jaggi AS. Poly(ADP-ribose) polymerase-1 (PARP-1) and its therapeutic implications. Vasc Pharmacol 2010;53:77–87.
19. 19 Szabó C, Lim LH, Cuzzocrea S, Getting SJ, Zingarelli B, Flower RJ, et al. Inhibition of poly (ADP-ribose) synthetase attenuates neutrophil recruitment and exerts antiinflammatory effects. J Exp Med 1997;186:1041–9.
20. 20 Gallí M, Van Gool F, Rongvaux A, Andris F, Leo O. The nicotinamide phosphoribosyltransferase: a molecular link between metabolism, inflammation, and cancer. Cancer Res 2010;70:8–11.
21. 21 Brailoiu E, Churamani D, Pandey V, Brailoiu GC, Tuluc F, Patel S, et al. Messenger-specific role for nicotinic acid adenine dinucleotide phosphate in neuronal differentiation. J Biol Chem 2006;281:15923–8.
22. 22 Araki T, Sasaki Y, Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 2004;305:1010–3.
23. 23 Chang J, Zhang B, Heath H, Galjart N, Wang X, Milbrandt J. Nicotinamide adenine dinucleotide (NAD)-regulated DNA methylation alters CCCTC-binding factor (CTCF)/cohesin binding and transcription at the BDNF locus. Proc Natl Acad Sci USA 2010;107:21836–41.
24. 24 Press C, Milbrandt J. NMNAT delays axonal degeneration caused by mitochondrial and oxidative stress. JNeurosci 2008;28:4861–71.
25. 25 Yahata N, Yuasa S, Araki T. Nicotinamide mononucleotide adenyltransferase expression in mitochondrial matrix delays Wallerian degeneration. J Neurosci 2009;29:6276–84.
26. 26 Mack TG, Reiner M, Beirowski B, Mi W, Emanuelli M, Wagner D, et al. Wallerian degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene. Nat Neurosci 2001;4: 1199–206.
27. 27 Zhai RG, Cao Y, Hiesinger PR, Zhou Y, Mehta SQ, Schulze KL, et al. Drosophila NMNAT maintains neural integrity independent of its NAD synthesis activity. PloS Biol 2006;4:2336–48.
28. 28 Zhai RG, Zhang F, Hiesinger PR, Cao Y, Haueter CM, Bellen HJ. NAD synthase NMNAT acts as a chaperone to protect against neurodegeneration. Nature 2008;452:887–91.
29. 29 Hegyi J, Schwartz RA, Hegyi V. Pellagra: dermatitis, dementia and diarrhea. Int J Dermatol 2004;43:1–5.
30. 30 Paulionis L, Kane SL, Meckling KA. Vitamin status and cognitive function in a long-term care population. BMC Geriatr 2005; 5:16.
31. 31 Goodwin JS, Goodwin JM, Garry PJ. Association between nutritional ststus and cognitive functioning in a healthy elderly population. JAMA 1983;249:2917–21.
32. 32 La Rue A, Koehler KM, Wayne SJ, Chiulli SJ, Haaland KY, Garry PJ. Nutritional status and cognitive functioning in anormally aging sample: a 6-y reassessment. Am J Clin Nutr 1997;65:20–9.
33. 33 Rex A, Hentschke MP, Fink H. Bioavailability of reduced nicotinamide-adenin-dinucleotide (NADH) in the central nervous system of the anaesthetized rat measured by laserinduced fluorescence spectroscopy. Pharmacol Toxicol 2002;90: 220–5.
34. 34 Young GS, Jacobson EL, Kirkland JB. Water maze performance in young male Long-Evans rats is inversely affected by dietary intakes of niacin and may be linked to levels of the NAD+ metabolite cADPR. J Nutr Biochem 2007;137:1050–7.
35. 35 Koppen A, Klein J, Schmidt BH, van der Staay FJ, Loffelholz K. Effects of nicotinamide on central cholinergic transmission and on spatial learning in rats. Pharmacol Biochem Behav 1996;53:783–90.
36. 36 van der Staay FJ, de Jonge M. Effects of age on water escape behavior and on repeated acquisition in rats. Behav Neural Biol 1993;60:33–41.
37. 37 Mohler H, Polc P, Cumin R, Pieri L, Kettler R. Nicotinamide is a brain constituent with benzodiazepine-like actions. Nature 1979;278:563–5.
38. 38 Rex A, Spychalla M, Fink H. Treatment with reduced nicotinamide adenine dinucleotide (NADH) improves water maze performance in old Wistar rats. Behav Brain Res 2004;154:149–53.
39. 39 Flicker L, Ames D. Metabolic and endocrinological causes of dementia. Internat Psychogeriatr 2005;17:S79–92.
40. 40 Blass JP. Brain metabolism and brain disease: is metabolic deficiency the proximate cause of Alzheimer dementia? J Neurosci Res 2001;66:851–6.
41. 41 Castellani R, Hirai K, Aliev G, Drew KL, Nunomura A, Takeda A, et al. Role of mitochondrial dysfunction in Alzheimer’s disease. J Neurosci Res 2002;70:357–60.
42. 42 Qin W, Yang T, Ho L, Zhao Z, Wang J, Chen L, et al. Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J Biol Chem 2006;280:21745–54.
43. 43 Braidy N, Guillemin G, Grant R. Promotion of cellular NAD(+) anabolism: therapeutic potential for oxidative stress in ageing and Alzheimer’s disease. Neurotox Res 2008;13:173–84.
44. 44 Jacobs RW, Farivar N, Butcher LL. Alzheimer dementia and reduced nicotinamide adenine dinucleotide (NADH)-diaphorase activity in senile plaques and the basal forebrain. Neurosci Lett 1985;53:39–44.
45. 45 Batlevi Y, La Spada AR. Mitochondrial autophagy in neural function, neurodegenerative disease, neuron cell death, and aging. Neurobiol Dis 2011;43:46–51.
46. 46 Hara T, Nakamura K, Matsui M, Yamamoto A, Nakahara Y, Suzuki-Migishima R, et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006;441:885–9.
47. 47 Komatsu M, Waguri S, Chiba T, Murata S, Iwata J, Tanida I, et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006;441:880–4.
48. 48 Li LB, Zhang XN, Le W. Autophagy dysfunction in Alzheimer’s disease. Neurodegen Dis 2010;7:265–71.
49. 49 Kristian T, Balan I, Schuh R, Onken M. Mitochondrial dysfunction and nicotinamide dinucleotide catabolism as mechanisms of cell death and promising targets for neuroprotection. J Neurosci Res 2011;89:1946–55.
50. 50 Green KN, Steffan JS, Martinez-Coria H, Sun X, Schreiber SS, Thompson LM, et al. Nicotinamide restores cognition in Alzheimer’s disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J Neurosci 2008;28:11500–10.
51. 51 Liu D, Gharavi R, Pitta M, Gleichmann M, Mattson MP. Nicotinamide prevents NAD+ depletion and protects neurons against excitotoxicity and cerebral ischemia: NAD+ consumption by SIRT1 may endanger energetically compromised neurons. Neuromolec Med 2009;11:28–42.
52. 52 Liu D, Pitta M, Jiang H, Lee JH, Zhang G, Chen X, et al. Nicotinamide forestalls pathology and cognitive decline in Alzheimer mice: evidence for improved neuronal bioenergetics and autophagy procession. Neurobiol Aging 2013;34:e3.
53. 53 Fischer A, Sananbenesi F, Pang PT, Lu B, Tsai LH. Opposing roles of transient and prolonged expression of p25 in synaptic plasticity and hippocampus-dependent memory. Neuron 2005; 48:825–38.
54. 54 Sasaki Y, Araki T, Milbrandt J. Stimulation of nicotinamide adenine dinucleotide biosynthetic pathways delays axonal degeneration after axotomy. J Neurosci 2006;26:8484–91.
55. 55 Chi Y, Sauve AA. Nicotinamide riboside, a trace nutrient in foods, is a vitamin B3 with effects on energy metabolism and neuroprotection. Curr Opin Clin Nutr Metab Care 2013;16: 657–61.
56. 56 Gong B, Pan Y, Vempati P, Zhao W, Knable L, Ho L, et al. Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-gamma coactivator 1alpha regulated beta-secretase 1 degradation and mitochondrial gene expression in Alzheimer’s mouse models. Neurobiol Aging 2013;34:1581–8.
57. 57 Demarin V, Podobnik SS, Storga-Tomic D, Kay G. Treatment of Alzheimer’s disease with stabilised oral nicotinamide adenine dinucleotide: a randomised, double-blind study. Drugs Exp Clin Res 2004;30:27–33.
58. 58 Birkmayer JGD. Coenzyme nicotinamide adenine dinucleotide – new therapeutic approach for improving dementia of the Alzheimer type. Ann Clin Labor Sci 1996;26:1–9.
59. 59 Rainer M, Kraxberger E, Haushofer M, Mucke HA, Jellinger KA. No evidence for cognitive improvement from oral nicotinamide adenine dinucleotide (NADH) in dementia. J Neural Transm 2000;107:1475–81.
60. 60 Morris MC, Evans DA, JL B, Scherr PA, Tangney CC, Herbert LE, et al. Dietary niacin and the risk of incident Alzheimer’s disease and of cognitive decline. J Neurol Neurosurg Psychiatry 2004;75:1093–9.
61. 61 Sadanaga-Akiyoshi F, Yao H, Tanuma S, Nakahara T, Hong JS, Ibayashi S, et al. Nicotinamide attenuates focal ischemic brain injury in rats: with special reference to changes in nicotinamide and NAD+ levels in ischemic core and penumbra. Neurochem Res 2003;28:1227–34.
62. 62 Yang J, He L, Wang J, Adams JDJ. Early administration of nicotinamide prevents learning and memory impairment in mice induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Pharmacol Biochem Behav 2004;78:179–83.
63. 63 Klawitter V, Morales P, Bustamante D, Goiny M, Herrera- Marschitz M. Plasticity of the central nervous system (CNS) following perinatal asphyxia: does nicotinamide provide neuroprotection? Amino Acids 2006;31:377–84.
64. 64 Morales P, Simola N, Bustamante D, Lisboa F, Fiedler J, Gebicke-Haerter PJ, et al. Nicotinamide prevents the longterm effects of perinatal asphyxia on apoptosis, non-spatial working memory and anxiety in rats. Exp Brain Res 2010;202: 1–14.
65. 65 Shen CC, Huang HM, Ou HC, Chen HL, Chen WC, Jeng KC. Protective effect of nicotinamide on neuronal cells under oxygen and glucose deprivation and hypoxia/reoxygenation. J Biomed Sci 2004;11:472–81.
66. 66 Tam D, Tam M, Maynard KI. Nicotinamide modulates energy utilization and improves functional recovery from ischemia in the in vitro rabbit retina. Ann N Y Acad Sci 2005;1053:258–68.
67. 67 Sutherland BA, Minnerup J, Balami JS, Arba F, Buchan AM, Kleinschnitz C. Neuroprotection for ischaemic stroke: translation from the bench to the bedside. Int J Stroke 2012;7: 407–18.
68. 68 Vonder Haar C, Peterson TC, Martens KM, Hoane MR. The use of nicotinamide as a treatment for experimental traumatic brain injury and stroke: a review and evaluation. Clin Pharmacol Biopharm 2013;S1:005.
69. 69 Hoane MR, Tan AA, Pierce JL, Anderson GD, Smith DC. Nicotinamide treatment reduces behavioral impairments and provides cortical protection after fluid percussion injury in the rat. J Neurotrauma 2006:10.
70. 70 Vonder Haar C, Anderson GD, Hoane MR. Continuous nicotinamide administration improves behavioral recovery and reduces lesion size following bilateral frontal controlled cortical impact injury. Behav Brain Res 2011;224:311–7.
71. 71 Goffus AM, Anderson GD, Hoane M. Sustained delivery of nicotinamide limits cortical injury and improves functional recovery following traumatic brain injury. Oxid Med Cell Longev 2010;3:145–52.
72. 72 Peterson TC, Anderson GD, Kantor ED, Hoane MR. A comparison of the effects of nicotinamide and progesterone on functional recovery of cognitive behavior following cortical contusion injury in the rat. J Neurotrauma 2012;29:2823–30.
73. 73 Swan AA, Chandrashekar R, Beare J, Hoane MR. Preclinical efficacy testing in middle-aged rats: nicotinamide, a novel neuroprotectant, demonstrates diminished preclinical efficacy after controlled cortical impact. J Neurotrauma 2011;28:431–40.
74. 74 Holland MA, Tan AA, Smith DC, Hoane MR. Nicotinamide treatment provides acute neuroprotection and GFAP regulationfollowing fluid percussion injury. J Neurotrauma 2008;25: 140–52.
75. 75 Anderson GD, Peterson TC, Farin FM, Bammler TK, Beyer RP, Kantor ED, et al. The effect of nicotinamide on gene expression in a traumatic brain injury model. Front Neurosci 2013;7:21.
76. 76 Jia H, Li X, Gao H, Feng Z, Li X, Zhao L, et al. High doses of nicotinamide prevent oxidative mitochondrial dysfunction in a cellular model and improve motor deficit in a Drosophila model of Parkinson’s disease. J Neurosci Res 2008:2083–90.
77. 77 Birkmayer JG, Vrecko C, Volc D, Birkmayer W. Nicotinamide adenine dinucleotide (NADH) – a new therapeutic approach to Parkinson’s disease. Comparison of oral and parenteral application. Acta Neurol Scand Suppl 1993;146:32–5.
78. 78 Dizdar N, Kågedal B, Lindvall B. Treatment of Parkinson’s disease with NADH. Acta Neurol Scand 1994;90:345–7.